Skip to main content
. Author manuscript; available in PMC: 2018 Oct 8.
Published in final edited form as: J Allergy Clin Immunol. 2017 Nov 17;142(4):1159–1172.e5. doi: 10.1016/j.jaci.2017.08.046

Figure 7. Established food-induced anaphylaxis is attenuated with ABL kinase inhibitor.

Figure 7

Experimental regimen (A), Maximum temperature change at the 6th and 7th challenge (± Imatinib) (B) the 7th challenge ± imatinib (C), percentage of mice with diarrhea (D), Hemacrit (%) (E) and serum mMCPT-1 levels (F) of OVA-sensitized WT BALB/c mice treated ± imatinib (1.27–1.75 mg/mice). Data are represented as the mean ± SD; n = 8 mice per group (D) and n = 7 – 8 per group except baseline n = 3 mice per group (E, F) from n = 2 experiments. (D) Ratio indicate number of mice with diarrhea: total number of mice. **** P < 0.0001, ** P < 0.01, * P < 0.05, ns > 0.05.